IL-24 Inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Panneerselvam, Janani ^a,b   Jin, Jiankang ^c,g   Shanker, Manish ^c,g   Lauderdale, Jason ^a,b   Bates, Jonathan ^a,b   Wang, Qi ^a,b   Zhao, Yan D ^a,b   Archibald, Stephen J ^d   Hubin, Timothy J ^b,e   Ramesh, Rajagopal ^a,b,f  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF HULL   (United Kingdom)

^e SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

^f Graduate Program in Biomedical Sciences   (United States)

^g UNIVERSITY OF TEXAS DENTAL BRANCH AT HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; G PROTEIN COUPLED RECEPTOR KINASE 6; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 24; MAMMALIAN TARGET OF RAPAMYCIN; PLERIXAFOR; PROTEIN KINASE B; SJA 5; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; HETEROCYCLIC COMPOUND; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER CELL LINE; METASTASIS INHIBITION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA STABILITY; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; DRUG SYNERGISM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS; HUMANS; INTERLEUKINS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84924975503     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122439     Document Type: Article

References (69)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Liu L, Zhao E, Li C, Huang L, Xiao L, Cheng L, et al. TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer. Cancer Epidemiol. 2013; 37: 71-78. doi: 10.1016/j.canep.2012.08.005 PMID: 22959342
3. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564. doi: 10.1126/science.1203543 PMID: 21436443
4. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/ CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003; 167: 1676-1686. PMID: 12626353
5. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267: 226-244. doi: 10.1016/j.canlet.2008.04.050 PMID: 18579287
6. Chu H, Zhou H, Liu Y, Liu X, Hu Y, Zhang J. Functional expression of CXC chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability. Int J Biochem Cell Biol. 2007; 39: 197-205. PMID: 16973405
7. Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res. 2005; 11: 8273-8280. PMID: 16322285
8. Oonakahara K, Matsuyama W, Higashimoto I, Kawabata M, Arimura K, Osame M. Stromal-derived fac-tor-1alpha/CXCL12-CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol. 2004; 30: 671-677. PMID: 14672915
9. Minamiya Y, Saito H, Takahashi N, Ito M, Imai K, Ono T, et al. Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2010; 68: 466-471. doi: 10.1016/j.lungcan.2009.07.015 PMID: 19716197
10. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 2009; 137: 615-621. doi: 10.1016/j.jtcvs.2008.07.039 PMID: 19258077
11. Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E, et al. Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol. 2008; 39: 1751-1755. doi: 10.1016/j.humpath.2008.04.017 PMID: 18701133
12. Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D, et al. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol. 2011; 6: 1169-1178. doi: 10.1097/JTO.0b013e3182199a99 PMID: 21623238
13. Wurth R, Bajetto A, Harrison JK, Barbieri F, Florio T. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci. 2014; 8: 144. doi: 10.3389/fncel.2014.00144 PMID: 24904289
14. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010; 16: 2927-2931. doi: 10.1158/1078-0432.CCR-09-2329 PMID: 20484021
15. Redjal N, Chan JA, Segal RA, Kung AL. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006; 12: 6765-6771. PMID: 17121897
16. Ali MM, Kumar S, Shankar A, Varma NR, Iskander AS, Janic B, et al. Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. Transl Oncol. 2013; 6: 660-669. PMID: 24466368
17. Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, et al. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med. 2001; 7: 271-282. PMID: 11471572
18. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002; 168: 6041-6046. PMID: 12055212
19. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol. 2002; 168: 5397-5402. PMID: 12023331
20. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol. 2006; 15: 991-1004. PMID: 17083366
21. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 2002; 20: 1069-1074. PMID: 11844832
22. Ishikawa S, Nakagawa T, Miyahara R, Kawano Y, Takenaka K, Yanagihara K, et al. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer. Clin Cancer Res. 2005; 11: 1198-1202. PMID: 15709189
23. Inoue S, Shanker M, Miyahara R, Gopalan B, Patel S, Oida Y, et al. MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic. Curr Gene Ther. 2006; 6: 73-91. PMID: 16475947
24. Panneerselvam J, Munshi A, Ramesh R. Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities. J Mol Signal. 2013; 8: 15. doi: 10.1186/1750-2187-8-15 PMID: 24377906
25. Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM, Chada S. Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther. 2004; 9: 510-518. PMID: 15093181
26. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/ IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005; 11: 160-172. PMID: 15585417
27. th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR. Cancer research. pp. 542.
28. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, et al. Melanoma differentiationassociated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 2003; 63: 5105-5113. PMID: 12941841
29. Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, et al. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med. 2002; 8: 451-461. PMID: 12435856
30. Ramesh R, Ito I, Saito Y, Wu Z, Mhashikar AM, Wilson DR, et al. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery. DNA Cell Biol. 2004; 23: 850-857. PMID: 15684712
31. Paschoud S, Dogar AM, Kuntz C, Grisoni-Neupert B, Richman L, Kühn LC. Destabilization of interleu-kin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-binding protein AUF1. Mol Cell Biol. 2006; 26: 8228-8241. PMID: 16954375
32. Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA, Ramesh R. Tumor-suppressive effects by adeno-virus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther. 2000; 7: 2051-2057. PMID: 11175318
33. Cohen P. Signal integration at the level of protein kinases, protein phosphatases and their substrates. Trends Biochem Sci. 1992; 17: 408-413. PMID: 1333658
34. Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol. 1998; 38: 289-319. PMID: 9597157
35. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem. 2010; 285: 7805-7817. doi: 10.1074/jbc.M109.091173 PMID: 20048153
36. Fife RS, SledgeGW Jr. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med. 1995; 125: 407-411. PMID: 7897308
37. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013; 13: 11-26. doi: 10.1038/nrc3419 PMID: 23258168
38. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014; 4: 64. doi: 10.3389/fonc.2014.00064 PMID: 24782981
39. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem. 2005; 280: 22473-22481. PMID: 15802268
40. Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH. Inhibition of chemokine (CXC motif) ligand 12/ chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem. 2012; 287: 12132-12141. doi: 10.1074/jbc.M111.302299 PMID: 22337890
41. Florio T, Casagrande S, Diana F, Bajetto A, Porcile C, Zona G, et al. Chemokine stromal cell-derived factor 1alpha induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals. Mol Pharmacol. 2006; 69: 539-546. PMID: 16258074
42. Clift IC, Bamidele AO, Rodriguez-Ramirez C, Kremer KN, Hedin KE. beta-Arrestin1 and distinct CXCR4 structures are required for stromal derived factor-1 to downregulate CXCR4 cell-surface levels in neuroblastoma. Mol Pharmacol. 2014; 85: 542-552. doi: 10.1124/mol.113.089714 PMID: 24452472
43. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006; 66: 32-48. PMID: 16114056
44. Ierano C, Santagata S, Napolitano M, Guardia F, Grimaldi A, Antignani E, et al. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis. 2014; 5: e1310. doi: 10.1038/ cddis.2014.269 PMID: 24991762
45. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013; 49: 219-230. doi: 10.1016/ j.ejca.2012.05.005 PMID: 22683307
46. Khan A, Nicholson G, Greenman J, Madden L, McRobbie G, Pannecouque C, et al. Binding optimization through coordination chemistry: CXCR4 chemokine receptor antagonists from ultrarigid metal complexes. J Am Chem Soc. 2009; 131: 3416-3417. doi: 10.1021/ja807921k PMID: 19231846
47. Lam WK, Watkins DN. Lung cancer: future directions. Respirology 2007; 12: 471-477. PMID: 17587411
48. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007; 98: 1652-1658. PMID: 17894551
49. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004; 14: 171-179. PMID: 15246052
50. Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. J Pathol. 2008; 215: 211-213. doi: 10.1002/path.2350 PMID: 18523970
51. Furusato B, Mohamed A, Uhlen M, Rhim JS. CXCR4 and cancer. Pathol Int. 2010; 60: 497-505. doi: 10.1111/j.1440-1827.2010.02548.x PMID: 20594270
52. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004; 18: 1240-1242. PMID: 15180966
53. Ramsey DM, McAlpine SR. Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett. 2013; 23: 20-25. doi: 10.1016/j.bmcl.2012.10.138 PMID: 23211868
54. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917-3924. doi: 10.1182/blood-2011-10-383406 PMID: 22308295
55. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214. doi: 10.1182/blood-2008-06-162123 PMID: 19050309
56. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006; 203: 2201-2213. PMID: 16940167
57. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009; 113: 6085-6093. doi: 10.1182/blood-2008-12-196618 PMID: 19380869
58. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA. 2007; 104: 15735-15740. PMID: 17898181
59. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2008; 283: 4283-4294. PMID: 18057003
60. Sun X, Wei L, Chen Q, Terek RM. CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer. 2010; 9: 17. doi: 10.1186/ 1476-4598-9-17 PMID: 20102637
61. Monterrubio M, Mellado M, Carrera AC, Rodriguez-Frade JM. PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion. Biochem Biophys Res Commun. 2009; 388: 199-204. doi: 10. 1016/j.bbrc.2009.07.153 PMID: 19660434
62. Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014; 90: 197-207. doi: 10.1016/j.bcp.2014.05.011 PMID: 24863259
63. Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, Moreno-Ortiz MC, Martinez AC, Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 1999; 13: 1699-1710. PMID: 10506573
64. Sauane M, Gopalkrishnan RV, Lebedeva I, Mei MX, Sarkar D, Su ZZ, et al. Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways. J Cell Physiol. 2003; 196: 334-345. PMID: 12811827
65. Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, et al. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 2004; 10: 1085-1095. PMID: 15564140
66. D'Alterio C, Barbieri A, Portella L, Palma G, Polimeno M, Riccio A, et al. Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol Immunother. 2012; 61: 1713-1720. PMID: 22399057
67. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert OpinInvestig Drugs. 2012; 21: 341-353. doi: 10.1517/13543784.2012.656197 PMID: 22283809
68. Uchida D, Onoue T, Kuribayashi N, Tomizuka Y, Tamatani T, Nagai H, et al. Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer. 2011; 47: 452-459. doi: 10. 1016/j.ejca.2010.09.028 PMID: 20965717
69. Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther. 2013; 6: 1347-1361. doi: 10. 2147/OTT.S36109 PMID: 24124379